Skip to main content

Advertisement

SpringerLink
Log in

Ischemic stroke prevention

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

More than 700,000 strokes occur annually in the United States—one every 40 to 50 seconds. Although stroke is one of the nation’s most expensive diseases to treat, costing $41 billion per year, most strokes (perhaps as many as two thirds) are preventable. Twenty percent of the United States population will have 80% of all strokes; this estimate is based on five established, major risk factors for stroke: hypertension, diabetes mellitus, cigarette smoking, hyperlipidemia, and heart disease. Therefore, stroke is not random but is generally predictable. It is an ideal target for effective prevention strategies that are simple and inexpensive. Ischemic stroke prevention has been shown to be effective in several scenarios: primary prevention, prevention after a transient ischemic attack (TIA), and secondary prevention. Dietary, lifestyle, and risk factor modification; use of aspirin, ticlopidine, clopidogrel, and warfarin; and carotid endarterectomy all have a role in stroke prevention in selected persons. Emerging therapies include the use of vitamins, cerebral arterial angioplasty, and stenting. Annual risk assessment, screening, and intervention should be part of a concerted national effort to reduce the incidence of the third leading cause of death and the number one cause of adult disability in the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Matchar DB, McCrory DC, Barnett HJM, Feussner JR: Medical treatment for stroke prevention. Ann Intern Med 1994, 121:41–53.

    PubMed  CAS  Google Scholar 

  2. American College of Physicians: Clinical guidelines for medical treatment for stroke prevention. Ann Intern Med 1994, 121:54–55.

    Google Scholar 

  3. Sacco RL, Benjamin EJ, Broderick JP, et al.: Risk factors. Stroke 1997, 28:1507–1517.

    PubMed  CAS  Google Scholar 

  4. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009. Important study showing the benefits of cholesterol reduction, even in patients with normal or modestly elevated cholesterol levels.

    Article  PubMed  CAS  Google Scholar 

  5. Bronner LL, Kanter DS, Manson JE: Primary prevention of stroke. N Engl J Med 1995, 333:1393–1400.

    Article  Google Scholar 

  6. Sacco RL, Elkind M, Boden-Albala B, et al.: The protective effect of moderate alcohol consumption on ischemic stroke. JAMA 1999, 281:53–60.

    Article  PubMed  CAS  Google Scholar 

  7. Antiplatelet Trialists’ Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988, 296:320–331.

    Article  Google Scholar 

  8. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81–106.

    Google Scholar 

  9. Peto R, Gray R, Collins R, et al.: Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988, 296:313–316.

    PubMed  CAS  Google Scholar 

  10. Steering Committee of the Physicians’ Health Study Research Group: Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989, 321:129–135.

    Article  Google Scholar 

  11. Hass WK, Easton JD, Adams HP, et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989, 321:501–507.

    Article  PubMed  CAS  Google Scholar 

  12. Gent M, Blakely JA, Easton JD, et al.: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989, 1:1215–1220.

    Article  PubMed  CAS  Google Scholar 

  13. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1998, 348:1329–1339.

    Google Scholar 

  14. Giraud-Chaumeil B, Rascol A, David J, et al.: Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires. Rev Neurol (Paris) 1982, 138:367–385.

    Google Scholar 

  15. Bousser MG, Eschwege E, Haguenau M, et al.: “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1985, 14:5–14.

    Google Scholar 

  16. The American-Canadian Co-operative Study Group: Persantine aspirin trial in cerebral ischemia. Part II: endpoint results. Stroke 1985, 16:406–415.

    Google Scholar 

  17. Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1–13.

    Article  PubMed  CAS  Google Scholar 

  18. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449–1457.

    Article  Google Scholar 

  19. Atrial Fibrillation Investigators: The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med 1997, 157:1237–1240.

    Article  Google Scholar 

  20. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343:687–691.

    Google Scholar 

  21. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixeddose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348:633–638. Study showing the lack of benefit of warfarin/aspirin combination therapy in patients with atrial fibrillation.

    Article  Google Scholar 

  22. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators: Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998, 279:1273–1277. Important analysis of patients with atrial fibrillation who do not require warfarin for stroke prevention.

    Article  Google Scholar 

  23. Azar AJ, Koudstaal PJ, Wintzen AR, et al.: Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction. Ann Neurol 1996, 39:301–307.

    Article  PubMed  CAS  Google Scholar 

  24. Khamashta MA, Cuadrado MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1994, 332:993–997.

    Article  Google Scholar 

  25. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997, 42:857–865.

    Article  Google Scholar 

  26. Chimowitz MI, Kokkinos J, Strong J, et al., for the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group: The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995, 45:1488–1493.

    PubMed  CAS  Google Scholar 

  27. Cannegieter SC, Rosendaal FR, Wintzen AR, et al.: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995, 333:11–17.

    Article  PubMed  CAS  Google Scholar 

  28. Harrison L, Johnston M, Massicotte MP, et al.: Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997, 126:133–136.

    PubMed  CAS  Google Scholar 

  29. Lamb GC: Loading dose of warfarin. JAMA 1997, 277:1196.

    Article  PubMed  CAS  Google Scholar 

  30. Wells PS, Holbrook AM, Crowther NR, Hirsh J: Interactions of warfarin with drugs and food. Ann Intern Med 1994, 121:676–683.

    PubMed  CAS  Google Scholar 

  31. Eckman MH, Levine HJ, Pauker SG: Decision analytic and cost-effectiveness issues concerning anticoagulant prophylaxis in heart disease. Chest 1992, 102:538S-549S.

    PubMed  CAS  Google Scholar 

  32. Bucher HC, Griffith LE, Guyatt GH: Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998, 128:89–95. Overview of cholesterol-reducing agents and their effect on stroke prevention.

    PubMed  CAS  Google Scholar 

  33. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991, 265:3255–3264.

    Article  Google Scholar 

  34. Murai A, Miyahara T, Fujimoto N, et al.: Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986, 59:199–204.

    Article  PubMed  CAS  Google Scholar 

  35. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977–986.

    Article  Google Scholar 

  36. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991, 325:445–453. Landmark study showing the benefit of carotid endarterectomy in symptomatic patients with severe stenosis.

    Article  Google Scholar 

  37. European Carotid Surgery Trialists’ Collaborative Group: Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998, 351:1379–1387.

    Article  Google Scholar 

  38. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study: Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995, 273:1421–1428.

    Article  Google Scholar 

  39. Moore WS, Vescera CL, Robertson JT, et al.: Selection process for surgeons in the Asymptomatic Carotid Atherosclerosis Study. Stroke 1991, 22:1353–1357.

    PubMed  CAS  Google Scholar 

  40. Wennberg DE, Lucas FL, Birkmeyer JD, et al.: Variation in mortality in the Medicare population. JAMA 1998, 279:1278–1281.

    Article  PubMed  CAS  Google Scholar 

  41. Lee TT, Solomon NA, Heidenreich PA, et al.: Cost-effectiveness of screening for carotid stenosis in asymptomatic persons. Ann Intern Med 1997, 126:337–346.

    PubMed  CAS  Google Scholar 

  42. Perry JR, Szalai JP, Norris JW, for the Canadian Stroke Consortium: Consensus against both endarterectomy and routine screening for asymptomatic carotid artery stenosis. Arch Neurol 1997, 54:25–28.

    PubMed  CAS  Google Scholar 

  43. Mathur A, Roubin GS, Iyer SS, et al.: Predictors of stroke complicating carotid artery stenting. Circulation 1998, 97:1239–1245.

    PubMed  CAS  Google Scholar 

  44. Diethrich EB, Ndiaye M, Reid DB: Stenting in the carotid artery: initial experience in 110 patients. J Endovasc Surg 1996, 3:42–62.

    Article  PubMed  CAS  Google Scholar 

  45. Theron JG, Payelle GG, Coskun O, et al.: Carotid artery stenosis: treatment with protected balloon angioplasty and stent placement. Radiology 1996, 201:627–636.

    PubMed  CAS  Google Scholar 

  46. Clark WM, Barnwell SL, Nesbit G, et al.: Safety and efficacy of percutaneous transluminal angioplasty for intracranial atherosclerotic stenosis. Stroke 1995, 26:1200–1204.

    PubMed  CAS  Google Scholar 

  47. Higashida RT, Tsai FT, Halbach VV, et al.: Transluminal angioplasty for atherosclerotic disease of the vertebral and basilar arteries. J Neurosurg 1993, 78(2):192–198.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wayne State University School of Medicine, 4201 St. Antoine, 48201, Detroit, MI, USA

    Seemant Chaturvedi MD & Steven R. Levine MD

  2. University of Michigan Medical Center, 1500 E. Medical Center Drive, 48109, Ann Arbor, MI, USA

    Susan Hickenbottom MD

Authors
  1. Seemant Chaturvedi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Hickenbottom MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven R. Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaturvedi, S., Hickenbottom, S. & Levine, S.R. Ischemic stroke prevention. Curr Treat Options Neurol 1, 113–125 (1999). https://doi.org/10.1007/s11940-999-0011-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-999-0011-y

Keywords

Search

Navigation